The broad objective of this research is to develop a Salmonella typhi- based live vector vaccine to prevent Plasmodium falciparum malaria. To achieve the broad objective we must successfully express in a suitable attenuated S. typhi strain protective antigens from the sporozoite, liver and asexual erythrocytic stages of P. falciparum and must demonstrate that these constructs can elicit the relevant types of immune responses in a mouse model. By independently attaining partial protection against the further development of each of these stages of the parasite, and by these effects working in concert, we will expect ultimately to have a vaccine that will prevent disease completely in some subjects and limit the severity of disease in others. At some future point, if sexual stage antigens are added, we might also expect to interfere with transmission of infection to susceptibles in the community. We will express in attenuated S. typhi strain CVD 908 (or further derivative strain CVD 908-htrA) antigens from the sporozoite (TBT) liver (SSP2) and asexual erythrocytic (MSP-1 carboxyl terminus and SERA N-terminus) stages of P. falciparum. We will attempt to enhance the serologic response by co-expressing a mutant heat-labile enterotoxin of Escherichia coli (""""""""K63"""""""") that exhibits powerful adjuvant activity but is non-toxic. We will also attempt to increase the stimulation of cytotoxic lymphocytes (CTLs) by modifying the S. typhi live vector so that it expresses the relevant plasmodial antigens (e.g., TBT, SSP2) of interest as secreted moieties. It is recognized that for intracellular bacteria such as Salmonella, that reside at length within phagosomes of macrophages, secreted proteins tend to elicit the earliest and strongest CTL responses. The mouse intranasal immunization model will be used to compare responses to individual constructs, mixtures of constructs and live vector co-expressing multiple foreign antigens. other research with CVD 908 and CVD 908-htrA live vectors expressing multiple foreign bacterial antigens has clearly demonstrated that it is possible to elicit strong, functional immune responses to the various multiple co-administered antigens.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI040297-03
Application #
2887289
Study Section
Tropical Medicine and Parasitology Study Section (TMP)
Program Officer
Hall, B Fenton
Project Start
1997-04-01
Project End
2000-06-30
Budget Start
1999-04-01
Budget End
2000-06-30
Support Year
3
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Galen, James E; Pasetti, Marcela F; Tennant, Sharon et al. (2009) Salmonella enterica serovar Typhi live vector vaccines finally come of age. Immunol Cell Biol 87:400-12
Chinchilla, Magaly; Pasetti, Marcela F; Medina-Moreno, Sandra et al. (2007) Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy. Infect Immun 75:3769-79
Vindurampulle, Christofer J; Cuberos, Lilian F; Barry, Eileen M et al. (2004) Recombinant Salmonella enterica serovar Typhi in a prime-boost strategy. Vaccine 22:3744-50
Pasetti, Marcela F; Levine, Myron M; Sztein, Marcelo B (2003) Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine 21:401-18
Gomez-Duarte, O G; Pasetti, M F; Santiago, A et al. (2001) Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparum sporozoite surface protein 2 in Salmonella vaccine strains. Infect Immun 69:1192-8
Wang, J Y; Pasetti, M F; Noriega, F R et al. (2001) Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915. Infect Immun 69:4734-41
Orr, N; Galen, J E; Levine, M M (2001) Novel use of anaerobically induced promoter, dmsA, for controlled expression of fragment C of tetanus toxin in live attenuated Salmonella enterica serovar Typhi strain CVD 908-htrA. Vaccine 19:1694-700
Levine, M M (2000) Immunization against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr 31:336-55
Tacket, C O; Sztein, M B; Wasserman, S S et al. (2000) Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 68:1196-201
Pasetti, M F; Pickett, T E; Levine, M M et al. (2000) A comparison of immunogenicity and in vivo distribution of Salmonella enterica serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine 18:3208-13

Showing the most recent 10 out of 19 publications